Kymera climbs as Fast Track KT-621 momentum and May conference catalysts fuel bid
KYMR•Kymera Therapeutics shares rose as investors continued to price in its April 30, 2026 Q1 update highlighting new FDA Fast Track designation for KT-621 in moderate-to-severe eosinophilic asthma and multiple near-term medical-meeting presentations in May. The company also reported $34.4 million in Q1 2026 collaboration revenue and ended March 31, 2026 with $1.55 billion in cash and marketable securities.
1. What’s moving the stock
Kymera Therapeutics (KYMR) is trading higher as the market continues to respond to the company’s first-quarter 2026 business update and near-term catalyst calendar. In that update, Kymera disclosed the FDA granted Fast Track designation to KT-621 for moderate-to-severe eosinophilic asthma, adding to a prior Fast Track designation in atopic dermatitis, and said it expects multiple presentations in May that keep attention on the KT-621 program and the broader targeted protein degradation pipeline. (investors.kymeratx.com)
2. The fundamentals investors are anchoring to
The April 30 release also provided fresh financial context, including $34.365 million in collaboration revenue for Q1 2026 and a cash, cash equivalents and marketable securities balance of about $1.546 billion as of March 31, 2026—supporting management’s statement that the company is well-capitalized with runway into 2029. (investors.kymeratx.com)
3. What to watch next
Near-term attention is centered on continued clinical execution in KT-621 and KT-579, plus conference visibility. Kymera said KT-621 Phase 2b studies in atopic dermatitis (BROADEN2) and asthma (BREADTH) are ongoing, with data expected by mid-2027 and late 2027, while KT-579 (IRF5) Phase 1 healthy-volunteer work is ongoing with data expected in the second half of 2026. (investors.kymeratx.com)
